Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory

NCT06361745 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06361745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06361745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
April 2, 2024
Completion date
March 1, 2025
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathies, igg4 related disease, primary sjögren syndrome, systemic lupus erythematosus, systemic sclerosis